Pulnovo Raises $100M Led by Medtronic to Advance PADN System for Pulmonary Hypertension

Why It Matters

The infusion of $100 million and Medtronic’s commercial muscle could fast‑track a novel, minimally invasive therapy for pulmonary hypertension, a disease with limited treatment options and a growing patient base.

Key Takeaways

• Pulnovo secured $100M financing led by Medtronic.
• Funding backs FDA Breakthrough PADN device development and IDE trial.
• Strategic agreement grants Medtronic global commercialization rights.
• Existing investors include EQT, Qiming, Gaorong, OrbiMed, Lilly Asia.
• PADN system targets pulmonary hypertension with minimally invasive therapy.

Pulse Analysis

Pulmonary hypertension (PH) remains a high‑mortality condition, affecting an estimated 1 million Americans and driving costly hospitalizations. Current pharmacologic options address symptoms but often fail to reverse vascular remodeling. Pulmonary artery denervation (PADN) offers a catheter‑based, minimally invasive approach to reduce pulmonary arterial pressure by disrupting sympathetic nerve activity, positioning it as a potentially disease‑modifying therapy.

Pulnovo’s recent $100 million raise, spearheaded by Medtronic, underscores strong investor confidence in PADN’s clinical promise. The round also includes strategic capital from EQT, Qiming, Gaorong, OrbiMed and Lilly Asia, reflecting a broad endorsement across venture and corporate investors. Coupled with a commercial partnership, Medtronic will leverage its extensive global sales infrastructure, regulatory expertise, and post‑market surveillance capabilities to accelerate market entry once FDA approval is secured.

If successful, the PADN system could reshape the PH treatment landscape, offering physicians a procedural alternative that complements existing drug regimens. The FDA Breakthrough Device designation already grants Pulnovo priority review pathways, shortening time to market. Moreover, the partnership may set a precedent for larger med‑tech firms to back early‑stage, device‑focused innovators, potentially spurring further investment in interventional solutions for chronic cardiopulmonary diseases. The combined clinical and commercial momentum positions Pulnovo to capture a sizable share of a market projected to exceed $5 billion globally within the next decade.